1. Introduction {#sec1-genes-08-00375}
===============

In 1996, Wu et al. in effort to understand the function of BRCA1 they used a yeast two-hybrid screen to identify proteins that associate with it in vivo \[[@B1-genes-08-00375]\]. By this analysis the BRCA1-associated RING domain 1 (BARD1) protein was discovered as a binding partner of BRCA1. BARD1 protein is encoded by sequences on chromosome 2q35 and forms a functional heterodimer with BRCA1 through the binding of their RING-finger domains which functions as tumor-suppressor in breast and ovarian cancer \[[@B1-genes-08-00375],[@B2-genes-08-00375],[@B3-genes-08-00375],[@B4-genes-08-00375]\]. The full length (FL) BARD1 mRNA includes 11 exons and encodes a protein comprising of one N-terminal RING-finger domain, three Ankyrin repeats (ANK) domains and two C-terminal BRCT domains ([Figure 1](#genes-08-00375-f001){ref-type="fig"}). The recognizable protein motifs of BARD1 are well conserved in mouse \[[@B5-genes-08-00375],[@B6-genes-08-00375]\], *Xenopus laevis* \[[@B7-genes-08-00375]\], *Caenorhabditis elegans* \[[@B8-genes-08-00375]\] and *Arabidopsis thaliana* \[[@B9-genes-08-00375]\], including the RING domain, the three tandem Ankyrin repeats and, to a lesser extent, the two BRCT domains. This complexity of structure indicates that BARD1 could have multiple functions.

Conditional inactivation of *Bard1* in mice induces mammary carcinomas that are indistinguishable from carcinomas induced by conditional knock-out of *Brca1*, which establishes BARD1 itself as a tumor suppressor \[[@B10-genes-08-00375]\]. The knock-out of *Brca1* and *Brca2* genes in mice led to embryonic lethality. Similarly, homozygous disruption of *Bard1* in mice results in lethality between embryonic days E7.5 and E8.5, at time when *Bard1* but not *Brca1* expression is maximal \[[@B5-genes-08-00375],[@B11-genes-08-00375]\]. The phenotype of *Bard1* knock-out mice demonstrated that *Bard1* is essential for cell viability and maintenance of genome integrity and embryos lethality only after eight days of development could mean that *Bard1* deficiency is deleterious to the cells. This hypothesis is supported by the finding that *BARD1* mutations are associated with few cases of non-*BRCA1/BRCA2*-related sporadic breast and ovarian tumors and account for only a small fraction of cases of familial breast cancer overall \[[@B12-genes-08-00375],[@B13-genes-08-00375],[@B14-genes-08-00375],[@B15-genes-08-00375],[@B16-genes-08-00375]\]. Interesting to note, *BRCA1* mutations do not immediately result in malignant phenotype but have cumulative effect that is possibly caused by incorrect stoichiometry with interacting proteins \[[@B17-genes-08-00375]\].

The BARD1-BRCA1 heterodimer has ubiquitin ligase activity that targets proteins involved in cell-cycle regulation, DNA repair, hormone signaling and modulating chromatin structure \[[@B18-genes-08-00375],[@B19-genes-08-00375]\]. Several reports show that BARD1 has an additional BRCA1-independent tumor suppressor function in cancer that is antagonized by the expression of BARD1 isoforms. Briefly, the expression of FL BARD1 (tumor suppressor role) is required for genomic stability and cell cycle control; in cancer initiation and progression the expression of BARD1 isoforms (oncogenes) antagonize FL BARD1 functions and permit uncontrolled proliferation ([Figure 1](#genes-08-00375-f001){ref-type="fig"}B) \[[@B5-genes-08-00375],[@B20-genes-08-00375],[@B21-genes-08-00375],[@B22-genes-08-00375],[@B23-genes-08-00375]\]. In the following review, we have focused on the genetic and molecular mechanisms of the dualistic role of BARD1 as oncogene and tumor-suppressor in cancer.

2. Rare and Common Cancer-Associated Genetic Variants of *BARD1* {#sec2-genes-08-00375}
================================================================

2.1. Rare Predisposing Variants of BARD1 in Cancer {#sec2dot1-genes-08-00375}
--------------------------------------------------

Mutations in the *BRCA1* and *BRCA2* genes are the most common causes of hereditary breast and ovarian cancer and are associated with a lifetime risk of breast cancer of 50--85% and of ovarian cancer of 15--40%. It is now apparent that mutations of several other genes, such as *BARD1*, *PALB2* (Partner And Localizer Of BRCA2) and *BRIP1* (BRCA1 Interacting Protein C-Terminal Helicase 1) \[[@B24-genes-08-00375]\], contribute to familial breast cancer. *BARD1* mutations are expected to account for additional cases of non-*BRCA1/2* inherited breast cancer and have been reported in non-*BRCA* mutated breast cancer families \[[@B25-genes-08-00375],[@B26-genes-08-00375],[@B27-genes-08-00375],[@B28-genes-08-00375]\]. A recent work has suggested *BARD1* as cancer-associated gene in ovarian cancer by a case-control association analysis between 1915 patients and Exome Sequencing Project (ESP, <http://varianttools.sourceforge.net/Annotation/EVS>) and Exome Aggregation Consortium (ExAC, <http://exac.broadinstitute.org>) controls \[[@B24-genes-08-00375]\]. The authors report a mutation frequency for *BARD1* of 0.2% and Odd Ratio of 4.2 (95% confidence interval: 1.4--12.5). Similar results have been presented by Couch et al. from multigene panel-based clinical testing for pathogenic variants in inherited cancer genes among patients with breast cancer \[[@B29-genes-08-00375]\]. The case-control association analysis between 38,326 white patients with breast cancer and 26,911 ExAC controls demonstrated an association between pathogenic rare variants in *BARD1* with a moderate risk value (Odd Ratio, 2.16; 95% confidence interval: 1.31--3.63) and a mutation frequency of 0.18% \[[@B29-genes-08-00375]\]. Thus, most of the published data are consistent with *BARD1* involvement in breast and ovarian cancers susceptibility \[[@B12-genes-08-00375],[@B13-genes-08-00375],[@B14-genes-08-00375],[@B15-genes-08-00375],[@B16-genes-08-00375],[@B25-genes-08-00375],[@B26-genes-08-00375],[@B27-genes-08-00375],[@B28-genes-08-00375],[@B29-genes-08-00375]\]. Indeed, *BARD1* is now included on clinical gene panels for testing for susceptibility to these two tumors. However, no recurrent hotspot variant has been identified so far.

Beyond single nucleotide variants, other types of risk mutations have been found in *BARD1* such as splicing mutations and large deletion. Interestingly, Ratajska et al. identified 16 *BARD1* mutations in *BRCA1/2*-negative high-risk breast and/ovarian cancer patients from Poland \[[@B30-genes-08-00375]\]. Among these mutations, a splice mutation (c.1315-2A \> G) resulted in exon 5 skipping and a silent change (c.1977A \> G) which altered several exonic splicing enhancer motifs in exon 10 and resulted in a transcript lacking exons 2--9 \[[@B30-genes-08-00375]\]. In a recent study, three *BARD1* mutations were identified that alter splicing leading to skipping of exons 5, 8 and 2--9, respectively \[[@B31-genes-08-00375]\].

The [Table 1](#genes-08-00375-t001){ref-type="table"} shows the list of mutations (*n* = 79) defined as "Pathogenic" and "Likely Pathogenic" in ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>). Most of mutations are loss-function due to deletion, nonsense or frame shift mutations and are associated with susceptibility to breast cancer ([Table 1](#genes-08-00375-t001){ref-type="table"} and [Figure 2](#genes-08-00375-f002){ref-type="fig"}). Only one missense mutation is reported even if recent literature reports diverse potential pathogenic missense mutations in *BARD1* \[[@B24-genes-08-00375],[@B29-genes-08-00375]\]. Moreover, others and we have demonstrated that *BARD1* is enriched in rare, potentially pathogenic, germline variants also in neuroblastoma patients \[[@B32-genes-08-00375],[@B33-genes-08-00375]\]. Particularly, the nonsense variant (rs587781948; exon 2), included in ClinVar, has been found in two patients in these two different gene-sequence projects. Based on these observations a curated update of *BARD1* mutations in ClinVar database is needed. We also expect that massive sequencing of *BARD1* in breast, ovarian cancers, neuroblastoma and other tumors will increase the number of rare pathogenic missense mutations to be inserted into the ClinVar database as "Pathogenic". However, these data strongly support the role of tumor-suppressor of BARD1 in different cancers.

Different copy number variants of *BARD1* locus have been found associated with congenital conditions (hypospadias and congenital heart defects: coarctation of aorta and tetralogy of fallot) and developmental phenotypes ([Table 1](#genes-08-00375-t001){ref-type="table"}) \[[@B34-genes-08-00375]\]. Neuroblastoma, tetralogy of fallot and coarctation of aorta are related to tissues that origin from neural crest cells. Moreover, literature data report cases of patients with coexisting neuroblastoma and congenital heart defects \[[@B35-genes-08-00375]\]. In 2004 George et al. demonstrated that congenital heart defects are more common in neuroblastoma patients than in a control group of children with another type of cancer \[[@B36-genes-08-00375]\]. Another study has demonstrated that depleting frog embryos of *BARD1* leads to defective developmental phenotypes (for instance: malformed neural tube and eye structures) \[[@B7-genes-08-00375]\]. Together, these evidences indicate that BARD1 might play a role in early organogenesis; however, additional studies are needed to demonstrate this hypothesis.

Although variants in protein-coding regions have received the most attention, numerous studies have noted the importance of non-coding variants in cancer. A sequencing of 20 complete genes, including noncoding and flanking sequences, in hereditary breast and ovarian cancer patients (*n* = 287) identified a single nucleotide variants in 5' UTR (c.-53G \> T; rs143914387) of *BARD1* predicted to alter the mRNA structure \[[@B37-genes-08-00375]\]. Further complete gene sequencing or whole genome sequencing projects are warranted to investigate the contribution of rare non-coding variants of *BARD1* in conferring cancer risk.

2.2. Common Predisposing Variants of BARD1 in Cancer {#sec2dot2-genes-08-00375}
----------------------------------------------------

Many genome-wide association studies (GWAS), using high-density single nucleotide polymorphism (SNP)-based microarray technology, have been conducted in the commonest cancer types and have identified more than 4032 genetic associations (GWAS catalog, date: 21 August 2017), confirming that susceptibility to these diseases is polygenic. We have performed a large GWAS to define the genetic landscape of sporadic neuroblastoma predisposition and have identified common DNA alleles in different genes \[[@B38-genes-08-00375],[@B39-genes-08-00375],[@B40-genes-08-00375],[@B41-genes-08-00375],[@B42-genes-08-00375],[@B43-genes-08-00375],[@B44-genes-08-00375],[@B45-genes-08-00375],[@B46-genes-08-00375],[@B47-genes-08-00375]\] that are associated significantly with neuroblastoma development. In that GWAS, one of the most significant and robustly replicated association signals that was enriched in the high-risk subset of neuroblastomas resided in the *BARD1* locus \[[@B21-genes-08-00375]\] that is also the only neuroblastoma susceptibility gene validated in Afro-American \[[@B48-genes-08-00375]\], Chinese \[[@B49-genes-08-00375]\] and Spanish individuals \[[@B50-genes-08-00375]\]. We have demonstrated that, in *BARD1* locus, SNPs associated with risk of neuroblastoma correlates with high expression of splice variants of BARD1 and SNPs protecting against neuroblastoma correlates with high expression of FL BARD1 \[[@B21-genes-08-00375]\]. Interestingly, one disease-associated variant (rs6435862) correlates with the expression of an oncogenetically activated isoform, BARD1β, which has growth-promoting effects in neuroblastoma models potentially through cooperation with the Aurora family of kinases \[[@B51-genes-08-00375]\]. Furthermore, by performing a fine mapping analysis of *BARD1* locus, we have identified additionally functional polymorphisms associated with risk of neuroblastoma and over-expression of FL BARD1 \[[@B50-genes-08-00375]\]. These data strongly suggest that the dual role of BARD1 as oncogene or tumor-suppressor is due to the function of disease-associated variants. Together, these evidences highlight that the risk of neuroblastoma development may be estimated by a specific combination of *BARD1* risk genotypes as suggested by the results of a published computational analysis of GWAS-identified neuroblastoma risk loci \[[@B52-genes-08-00375]\].

Recently, the SNP rs7585356 previously associated to neuroblastoma has been found also associated to nephroblastoma \[[@B53-genes-08-00375]\], which is the most frequent malignant renal tumor in children. Although the SNP rs7585356 located in 3' UTR of *BARD1* may have a role in BARD1 mRNA regulation, additional investigations are needed to validate this genetic association.

Candidate gene association studies have suggested that the low-frequency variant Cys557Ser (rs28997576) confers risk of single and multiple primary breast cancers in Icelandic \[[@B26-genes-08-00375]\] and South American \[[@B54-genes-08-00375]\] populations. However, independent studies failed to replicate that genetic association in Polish \[[@B55-genes-08-00375]\], multiethnic \[[@B56-genes-08-00375]\], Chinese \[[@B57-genes-08-00375]\], Australian \[[@B58-genes-08-00375]\] individuals. We also failed to validate that genetic association in a case series consisting of 540 high-risk neuroblastoma cases and 1142 controls \[[@B46-genes-08-00375]\] with European-American origins. These discordant results might be due to population substructure or gene modifiers affecting the role of BARD1 in cancer development.

2.3. Somatic Mutations of BARD1 in Cancer {#sec2dot3-genes-08-00375}
-----------------------------------------

Whereas common and rare hereditable variants of *BARD1* have been associated with cancer risk, recent high-throughput sequencing studies have found no frequently acquired somatic mutations in tumor tissues. In accord to previous studies, our exome and deep sequencing of 82 clinically aggressive neuroblastomas detected only one somatic acquired mutation \[[@B32-genes-08-00375]\]. Interestingly, a large whole exome sequencing study on 500 metastatic cancers identified *BARD1* among the genes somatically altered at low-frequency \[[@B59-genes-08-00375]\] and recently *BARD1* has been included in the list of Cancer Gene Census in COSMIC database (<http://cancer.sanger.ac.uk/census>.). Here we have analyzed all somatic mutations of *BARD1* deposited in COSMIC database by using the Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM) \[[@B60-genes-08-00375]\] tool to distinguish passenger variation events from driver ones across a cohort of tumors and the Variant Effect Scoring Tool (VEST) \[[@B61-genes-08-00375]\] to identify variants that affect the molecular function of the protein and prioritize them on the basis of the likelihood of their involvement in human disease ([Table 2](#genes-08-00375-t002){ref-type="table"}). We confirm that even if pathogenic somatic mutations are relatively infrequent, *BARD1* can be considered a cancer driver gene (CHASM gene score = 0.73; CHASM gene *p*-value = 0.0000004).

3. Biological Functions of BARD1 as Tumor Suppressor {#sec3-genes-08-00375}
====================================================

Tumor suppressor functions of BRCA1 are thought to be mediated by the BARD1-BRCA1 heterodimer which is an E3 ubiquitin ligase implicated in DNA repair \[[@B18-genes-08-00375],[@B19-genes-08-00375]\] and in other essential functions for maintaining genomic stability \[[@B62-genes-08-00375],[@B63-genes-08-00375]\], as homologous recombination \[[@B64-genes-08-00375]\], centrosome duplication \[[@B62-genes-08-00375]\] and mitotic spindle assembly \[[@B65-genes-08-00375]\] ([Figure 3](#genes-08-00375-f003){ref-type="fig"}). Specific functions of BARD1-BRCA1 heterodimer will not be dealt with in this paragraph. Although partner of this complex, FL BARD1 initiates or facilitates DNA repair pathways by controlling polyadenylation machinery in BRCA1-independent way through BARD1 binding with mRNA polyadenylation factor cleavage stimulation factor (CSTF1) \[[@B66-genes-08-00375],[@B67-genes-08-00375]\].

BARD1 expression fluctuates in a cell-cycle dependent manner, with maximal expression levels occurring in mitosis \[[@B73-genes-08-00375]\]. In mitosis FL BARD1 stability is increased due to phosphorylation by cell-cycle dependent kinase complexes (cyclin A/E-CDK2 and cyclin B-CDK2) within regions required for ubiquitin ligase activity of BARD1-BRCA1 heterodimer \[[@B74-genes-08-00375]\]. Contrary, BRCA1 is mostly expressed during S-phase of cell-cycle \[[@B73-genes-08-00375]\]. We can speculate that the concomitant expression of BARD1 and BRCA1 in S-phase support the function of BARD1-BRCA1 heterodimer and FL BARD1 expression in mitosis supports additional BRCA1-independent functions.

BRCA1 and BARD1 have specific individual functions due to their interaction with various proteins and the dissociation of heterodimer might be regulated by post-translation protein modifications such as phosphorylation, ubiquitination or PARylation. Cancer-associated BRCA1-independent activities of BARD1 have been reported in various tumor cell lines ([Figure 3](#genes-08-00375-f003){ref-type="fig"}). An access of monomer BARD1 over BRCA1 has been associated with *BRCA1* mutations and with p53-mediated apoptosis. The link between BARD1 and apoptosis has been further highlighted by BARD1 co-immunoprecipitation with p53 in tissues exposed to genotoxic stress \[[@B70-genes-08-00375],[@B71-genes-08-00375]\]. Particularly, the region of BARD1 binding with p53 involves ANK repeats and the region between ANK and BRCT domains in BARD1-C terminal fragment \[[@B72-genes-08-00375]\]. It is interesting to note that mutations or deletions in *TP53* gene are frequent in cancer with *BRCA1* mutations \[[@B75-genes-08-00375],[@B76-genes-08-00375]\]. We can speculate that *BRCA1* mutated tumors save BARD1 pro-apoptotic functions and additional *TP53* mutations may enhance cancer development. Contrary deleterious *BARD1* mutations are infrequent in cancer because the cells lose both DNA repair capabilities and pro-apoptotic function. BARD1 is also transcriptionally up-regulated in response to genotoxic stress and in brain after hypoxia suggesting that BARD1 is expressed specifically in tissues undergoing apoptosis \[[@B71-genes-08-00375]\].

BARD1 is involved in transcription factor NF-κB pathway. The binding of C-terminal fragment of BARD1 to the ANK repeats domain of BCL3, a NF-κB inhibitor in vitro, may affect the correct regulation of NF-κB in cancer and inflammatory and autoimmune diseases \[[@B68-genes-08-00375]\]. Emerging evidences report the interaction of BARD1 BRCT domain to poly(ADP-ribose) (PAR) and consequent recruitment of BARD1-BRCA1 complex to DNA repair after damage \[[@B69-genes-08-00375]\]. PAR pathway is particularly interesting because of the promising drugs act on inhibiting PAR polymerizing enzyme (PARP) are more efficient in cells *BRCA1* mutated with saved BARD1 tumor suppressor function. Finally, a significant association found between over-expression of FL BARD1 and favorable outcome in colon cancer patients highlighted FL BARD1 function as prognostic factor in cancer \[[@B20-genes-08-00375]\].

4. Biological Functions of BARD1 as Oncogene {#sec4-genes-08-00375}
============================================

BARD1 is characterized by full length and diverse spliced isoforms ([Figure 1](#genes-08-00375-f001){ref-type="fig"}). Down-regulation of FL BARD1 can have oncogenic effects \[[@B5-genes-08-00375],[@B11-genes-08-00375],[@B20-genes-08-00375],[@B21-genes-08-00375]\] whereas BARD1 isoforms that lack RING or/and ANK domains are often up-regulated and associated with negative prognosis in breast \[[@B15-genes-08-00375]\], ovarian \[[@B15-genes-08-00375]\] endometrial \[[@B77-genes-08-00375]\] and lung \[[@B78-genes-08-00375]\] cancers. Several scientific evidences show that cancer-associated BARD1 isoforms antagonize the functions of FL BARD1 as tumor suppressor and act as a driving force for carcinogenesis.

BARD1β and BARD1δ isoforms were first identified in rat spermatocytes and in a highly tumorigenic and resistant to apoptosis rat ovarian cancer cell line NuTu-19 \[[@B70-genes-08-00375],[@B79-genes-08-00375]\]. BARD1β is characterized by lack of exons 2 and 3 and encode to a protein lacking the RING finger and BRCA1 domain interaction. In breast and ovarian cancer an imbalance of FL BARD1 and BARD1β was observed with BARD1β dominant negative function. BARD1β scaffolds Aurora B and BRCA2 at the midbody during telophase and cytokinesis, antagonizing Aurora B ubiquitination and degradation by BARD1-BRCA1 E3 ubiquitin ligase \[[@B22-genes-08-00375]\]. BARD1β oncogenic driver of tumorigenesis is also supported by GWAS that identified *BARD1* as new susceptibility locus in neuroblastoma as mentioned above \[[@B51-genes-08-00375]\]. BARD1β depletion in vitro caused genotype-specific inhibition of cell proliferation in neuroblastoma cells, whereas overexpression of BARD1β led to the transformation of non-malignant murine fibroblast \[[@B51-genes-08-00375],[@B77-genes-08-00375]\].

BARD1δ is characterized by deletion of exons 2--6 that encode for the majority of the RING finger and the entirety of the ANK repeats, critical regions for the interaction with BRCA1 and p53; this isoform was detected in many gynecological cancers and in multiple processes of tumorigenesis \[[@B70-genes-08-00375],[@B80-genes-08-00375],[@B81-genes-08-00375]\]. In MCF-7 cells, BARD1δ does not stimulate apoptosis due to p53 deficiency \[[@B80-genes-08-00375]\]; however, its mitochondrial localization suggested a function in regulation of mitochondrial response to tumorigenic stress \[[@B82-genes-08-00375]\]. Interestingly, BARD1δ specifically binds to estrogen receptor alpha (ERα) antagonizing ERα-BARD1 binding and ERα degradation \[[@B83-genes-08-00375]\]. To note, BARD1δ dominant negative of FL BARD1 is temporally and spatially regulated by estrogen signaling in human invasive cytotrophoblasts cells of early pregnancy \[[@B81-genes-08-00375]\]. Recently, Maxim Pilyugin et al. described BARD1δ antagonizes chromosome and telomere protection function of BARD1-BRCA1 heterodimer by binding molecules that confer chromosome integrity \[[@B84-genes-08-00375]\]. It is likely that BARD1δ confers genomic instability and acquired oncogenic property in absence of cell cycle control, due to p53 deficiency and of chromosome integrity.

BARD1ω isoform contains only exons 6--11 encoding ANK repeats and BRCT domain. This isoform was found highly expressed in acute myeloid leukemia (AML) and in AML cell lines. In vitro BARD1ω overexpression induced multiple mitotic defects like aberrant chromosome alignment at the metaphase and anaphase state, abnormally increased size of nucleus and apoptosis inhibition. These scientific evidences highlight oncogenic proprieties of BARD1ω \[[@B85-genes-08-00375]\].

5. Summary and Future Perspectives {#sec5-genes-08-00375}
==================================

In this review, we summarized the genetic and molecular mechanisms associated to a dualistic role of BARD1 in cancer initiation: tumor suppressor and oncogene. *BARD1* shows relatively low frequent mutations in cancer and, even if rare, *BARD1* mutations seem to drive malignant transformation. The reduced expression of FL BARD1 due to somatic mutations or predisposition gene silencing variants may be considered the first hit of BARD1 tumor suppressor function. Instead, FL BARD1 loss-of function consequently to aberrant splicing and gain of dominant negative functions is associated with its proto-oncogenic role. Indeed, cancer associated BARD1 isoforms antagonize the functions of FL BARD1 as tumor suppressor and lead to genetic instability, loss of DNA repair and cell cycle control functions and permits uncontrolled proliferation. This antagonist effect is also supported from a more recently published research article that suggests that specific microRNAs, in healthy tissues, maintain an equilibrium of FL BARD1 and isoforms in favor of FL BARD1 instead, in cancer cells, create a disequilibrium in favor of BARD1 isoforms upon epigenetic activation of non-coding BARD1 isoform BARD1 9'L \[[@B23-genes-08-00375]\].

In ClinVar database, beyond deletion, nonsense or frame shift mutations, only one missense mutation of *BARD1* is reported as "Pathogenic" even if recent literature demonstrates the association of common and rare point mutations with cancer initiation \[[@B29-genes-08-00375],[@B86-genes-08-00375]\]. Thus, further functional investigations of non-coding and coding disease-associated variants are needed in order to verify their role in tumorigenesis and drug response.

BARD1 might also play a role in early organogenesis and in diseases related to tissues that origin from neural crest cells. In light of these evidences additional studies to explore BARD1 function in cancer and in developmental disorders should be considered in the next future.

BARD1 as Possible Biomarker and Therapeutic Possibilities
---------------------------------------------------------

BARD1β has been identified as an oncogenic driver of high-risk neuroblastoma tumorigenesis and a stabilizer of Aurora family of kinases. This strongly supports the development of potential therapeutic strategy with Aurora kinase inhibitors for clinically aggressive neuroblastoma. Moreover, the switching from FL BARD1 to BARD1β permits the deregulated turnover of the Aurora kinases. Thus, Aurora and BARD1β expression levels might be predictive biomarkers for response to Aurora inhibitors.

Protein PARylation functions as a signal to recruit DNA damage repair proteins like the BARD1-BRCA1 complex to repair Double Strand Breaks (DSBs). BARD1 BRCTs bind ADP-ribose, the basic unit of PAR, at DNA damage sites which mediates the rapid recruitment of BRCA1. PARP inhibition directly suppresses the fast recruitment of the BARD1-BRCA1 heterodimer to DNA damage sites and impairs DNA repair. PARP inhibitors (PARPi) selectively kill BRCA1-deficient cells and several PARPi are currently in breast cancer clinical trials. However, the mechanism underlying the sensitivity of the tumor cells bearing *BRCA1* mutations that abolish the interaction between BRCA1 and BARD1 to PARPi is not clear \[[@B87-genes-08-00375]\]. Ovarian and breast cancer patients who harbor *BRCA1* mutations develop resistance to both PARPi and platinum therapy \[[@B88-genes-08-00375],[@B89-genes-08-00375]\]. Secondary mutations in *BRCA* genes as well as gene methylation status for *BRCA1*, *BRCA2* and other genes that control homologous recombination have been examined in patients' biopsies as potential resistance mechanisms. One way to overcome clinical resistance is to investigate as the expression of FL or isoform BARD1 could contribute to the success or failure of PARPi therapy. A recent paper has demonstrated that BARD1β sensitizes colon cancer cells to poly PARP-1 inhibition even in a FL BARD1 background, thus suggesting that BARD1β may serve as a future biomarker to assess suitability of colon cancers for homologous recombination targeting with PARPi in treatment of advanced colon cancer \[[@B90-genes-08-00375]\]. In the future, it will be interesting to evaluate the efficacy of PARPi in patients with loss-of-function mutations of *BARD1* that are relatively frequent ([Table 1](#genes-08-00375-t001){ref-type="table"}).

The early detection of cancer is the most important factor contributing to the total eradication of cancer. The over-expression of BARD1 isoforms is strongly correlated with tumor progression, specifically in non-small-cell lung cancer (NSCLC) \[[@B20-genes-08-00375],[@B51-genes-08-00375],[@B78-genes-08-00375]\]. Based on these evidences Irminger-Finger et al. have developed a blood test for the early detection and diagnosis of lung cancer based on capturing autoimmune antibodies against BARD1 antigens \[[@B91-genes-08-00375]\]. Additional studies are needed to verify the efficacy of this test in detection of lung cancer and it will be very interesting to extend this experimentation to other cancers such as neuroblastoma, ovarian and breast cancer.
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![Structure of BRCA1-associated RING domain 1 (BARD1) and spliced isoforms. (**A**) Full-length (FL) BARD1 exon structure is aligned with spliced BARD1 isoforms below and protein structure above. The protein domains are reported at top of the figure. Splice variants are named with Greek letters (left). Presumed protein coding exons are shown in blue colors; non-coding exons are shown in white (β, κ, γ, η); asterisk shows alternative open reading frames (β, γ and η). Amino acid (aa) number is reported for FL BARD1 and BARD1 isoforms; (**B**) Model for dual role of BARD1 in cancer. In normal cells BARD1 isoforms (β, δ, ω isoforms, discussed in "Biological Functions of BARD1 as Oncogene" paragraph) are not expressed; in cancer cells, full-length BARD1 (FL) expression (tumor suppressor role of BARD1) decreases and BARD1 isoforms expression (oncogenic role of BARD1) increases. [Figure 1](#genes-08-00375-f001){ref-type="fig"} has been modified from Irmgard Irminger-Finger et al. \[[@B3-genes-08-00375]\].](genes-08-00375-g001){#genes-08-00375-f001}

![BARD1 germline coding mutations. The protein domains RING (green), Ankyrin (ANK, red), BRCA1 carboxy-terminal (BRCT, orange) are indicated. Coding mutations of BARD1 defined as "Pathogenic" and "Likely Pathogenic" in ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>) are shown. The red arrows indicate the mutations categorized as "Likely Pathogenic", the other mutations without the arrow are categorized as "Pathogenic".](genes-08-00375-g002){#genes-08-00375-f002}

![Full-length (FL) BARD1 pathways and functions. FL BARD1 participates in two major pathways as tumor suppressor. (**A**) BRCA1-independent pathways are mediated by the interaction of BARD1 with proteins involved in oncogenic pathways. BARD1 has transcriptional activity as it can induce the transcription activity of NF-κBs through binding to the NF- κB co-factor BCL3 \[[@B68-genes-08-00375]\]. FL BARD1 interacts to poly(ADP-ribose) (PAR) after damage and consequently it is recruited to DNA repair \[[@B69-genes-08-00375]\]. Finally, increased expression levels of FL BARD1 stabilize p53 and facilitate its phosphorylation by DNA-dependent protein kinase (DNAPK) \[[@B70-genes-08-00375],[@B71-genes-08-00375],[@B72-genes-08-00375]\]; (**B**) BRCA1-dependent pathways are mediated by BARD1-BRCA1 heterodimer. The activity of the BARD1-BRCA1 ubiquitin ligase is implicated in essential functions for maintaining genomic stability \[[@B61-genes-08-00375],[@B62-genes-08-00375],[@B63-genes-08-00375],[@B64-genes-08-00375]\].](genes-08-00375-g003){#genes-08-00375-f003}

genes-08-00375-t001_Table 1

###### 

Pathogenic and Likely pathogenic rare mutations of *BARD1* reported in ClinVar database.

  Variation ID   GRCh37 Location        Ref.   Alt    Mutation Type                    Protein Change   dbSNP          Frequency in ExAC Database   Condition(s)                                                                             Clinical Significance (Last Reviewed)
  -------------- ---------------------- ------ ------ -------------------------------- ---------------- -------------- ---------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  237823         .                      .      .      deletion                         .                .              .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 10 December 2015)
  230523         215593433--215593434   TG     \-     frameshift deletion              V767fs           rs750413473    0.00006                      Familial cancer of breast\|not specified\|Hereditary cancer-predisposing syndrome        Conflicting interpretations of pathogenicity (Last reviewed: 18 August 2016)
  185366         215593466              G      A      nonsense                         W756 \*          rs786202118    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 20 June 2014)
  187542         215593585--215593586   CA     \-     frameshift deletion              I717fs           rs786203811    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 10 December 2014)
  422826         215593671              A      AA     frameshift duplication           D689fs           .              .                            not provided                                                                             Likely pathogenic (Last reviewed: 29 November 2016)
  265365         215593734              A      C      splice acceptor                  .                rs876658260    .                            not provided                                                                             Likely pathogenic (Last reviewed: 28 June 2016)
  229902         215593734              A      T      splice acceptor                  .                rs876658260    .                            Hereditary cancer-predisposing syndrome                                                  Likely pathogenic (Last reviewed: 17 November 2015)
  182051         215595140              C      T      nonsense                         Q666 \*          rs730881422    .                            Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic/Likely pathogenic (Last reviewed: 13 January 2017)
  187445         215595166              C      \-     frameshift deletion              P657fs           rs786203739    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 3 March 2016)
  430952         215595182--215595201                 frameshift duplication           Q652fs           .              .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 13 April 2017)
  265510         215595182--215595201                 frameshift deletion              C645fs           rs886039589    .                            not provided                                                                             Likely pathogenic (Last reviewed: 3 December 2015)
  127725         215595182--215595201                 frameshift duplication           Q652fs           rs587780024    .                            Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic/Likely pathogenic (Last reviewed: 13 April 2017)
  142499         215595203--215595204   AT     \-     frameshift deletion              C645fs           rs587782504    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic/Likely pathogenic (Last reviewed: 20 November 2015)
  141702         215595215              C      T      nonsense                         R641 \*          rs587781948    0.00001                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 4 October 2016)
  232108         215595234              A      \-     splice acceptor                  .                rs876659560    .                            Hereditary cancer-predisposing syndrome                                                  Likely pathogenic (Last reviewed: 29 May 2015)
  219763         215595234              A      T      splice acceptor                  .                rs864622239    .                            Familial cancer of breast                                                                Likely pathogenic (Last reviewed: 8 August 2015)
  233167         215609790              G      T      splice donor                     .                rs876660237    .                            Hereditary cancer-predisposing syndrome                                                  Likely pathogenic (Last reviewed: 6 August 2015)
  232127         215609822              T      \-     frameshift deletion              L625fs           rs876659572    .                            not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 26 July 2016)
  143017         215609876--215609877   AT     \-     frameshift deletion              H606fs           rs587782897    .                            not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 8 June 2016)
  245801         215609884              G      A      splice acceptor                  .                rs879253952    .                            not provided                                                                             Pathogenic (Last reviewed: 9 June 2015)
  246449         215609885--215609893          \-     splice acceptor                  .                rs879254264    .                            not provided                                                                             Likely pathogenic (Last reviewed: 7 March 2016)
  232643         215610445              G      A      splice donor                     .                rs876659894    .                            Hereditary cancer-predisposing syndrome                                                  Likely pathogenic (Last reviewed: 30 June 2015)
  127720         215610566              C      T      nonsense                         Q564\*           rs587780021    0.00005                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 3 January 2017)
  406791         215617170              G      C      splice donor                     .                rs1060501310   .                            Familial cancer of breast                                                                Likely pathogenic (Last reviewed: 2 August 2016)
  141384         215617196              C      G      nonsense                         S551 \*          rs587781707    .                            Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 29 December 2016)
  230172         215617209              G      T      nonsense                         E547 \*          rs876658429    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 28 January 2015)
  406768         215617214--215617248                 frameshift indel                 T534fs           rs1064792931   .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 22 September 2016)
  379750         215617226              C      A      nonsense                         S541 \*          rs777937955    .                            not provided                                                                             Pathogenic (Last reviewed: 14 May 2015)
  406776         215632275              \-     A      frameshift duplication           D500fs           .              .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 13 August 2016)
  421820         215633955              \-     G      splice donor duplication         .                .              .                            not provided                                                                             Likely pathogenic (Last reviewed: 4 August 2016)
  233414         215634002              \-     A      frameshift duplication           N450fs           rs876660390    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 17 August 2015)
  406748         215634026              C      \-     frameshift deletion              P442fs           rs1060501287   .                            Familial cancer of breast\|not provided                                                  Pathogenic/Likely pathogenic (Last reviewed: 20 September 2016)
  243116         215645314              A      \-     frameshift deletion              E429fs           rs879253879    .                            not provided                                                                             Likely pathogenic (Last reviewed: 11 December 2015)
  234190         215645328              A      \-     frameshift deletion              R424fs           rs876660911    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 2 October 2015)
  187182         215645331--215645334   GTG    ATG    frameshift indel                 V422fs           rs786203533    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 10 November 2014)
  229677         215645382              C      T      nonsense                         R406 \*          rs377153250    0.00003                      Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 11 November 2014)
  142734         215645386              C      G      nonsense                         Y404 \*          rs587782681    .                            Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 13 October 2016)
  379884         215645393              C      G      nonsense                         S402 \*          rs796666047    .                            not provided                                                                             Pathogenic (Last reviewed: 1 June 2015)
  187646         215645400              A      \-     frameshift deletion              S400fs           rs786203891    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 17 December 2014)
  237814         215645426              C      G      nonsense                         S391 \*          rs878853995    .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 24 February 2016)
  185916         215645537              C      G      nonsense                         S354 \*          rs786202559    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 24 March 2016)
  232902         215645575              G      \-     frameshift deletion              S342fs           rs876660061    .                            not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 21 July 2015)
  419156         215645584              C      \-     frameshift deletion              S339fs           rs1064793682   .                            not provided                                                                             Pathogenic (Last reviewed: 1 June 2015)
  141412         215645651              T      G      nonsense                         L316 \*          rs587781728    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 7 April 2014)
  185015         215645737--215645738   AG     \-     frameshift deletion              E287fs           rs786201868    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 29 May 2014)
  232418         215645759--215645760   TT     \-     frameshift deletion              L280fs           rs876659752    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 15 June 2015)
  406757         215645853              \-     A      frameshift duplication           I249fs           .              .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 24 October 2016)
  141005         215645865              C      T      nonsense                         Q245 \*          rs587781430    0.00001                      not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 8 March 2017)
  230107         215645889              C      T      nonsense                         Q237 \*          rs587780035    .                            not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 11 July 2016)
  141342         215645938--215645941   TTTA   \-     frameshift deletion              R219fs           rs587781671    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 23 February 2014)
  219726         215645970--215645971   AA     \-     frameshift deletion              K209fs           rs864622223    .                            Familial cancer of breast\|not provided                                                  Pathogenic/Likely pathogenic (Last reviewed: 4 December 2015)
  127742         215645975              \-     A      frameshift deletion              K209fs           rs587780033    .                            Familial cancer of breast\|Hereditary cancer-predisposing syndrome                       Pathogenic (Last reviewed: 18 November 2016)
  182042         215645991              G      T      nonsense                         G203 \*          rs730881415    .                            not provided                                                                             Pathogenic (Last reviewed: 25 September 2014)
  233965         215646006              G      \-     frameshift deletion              A198fs           rs876660761    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 15 September 2015)
  186576         215646058--215646059   AT     \-     frameshift deletion              Y180fs           rs779427628    0.00001                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 13 December 2016)
  406761         215646072              C      T      nonsense                         Q176 \*          rs776851287    .                            Familial cancer of breast                                                                Pathogenic (Last reviewed: 26 May 2016)
  185846         215646102              C      T      nonsense                         Q166 \*          rs786202500    .                            not provided\|Hereditary cancer-predisposing syndrome                                    Pathogenic (Last reviewed: 4 April 2016)
  230344         215646138--215646141   \-     AAAG   frameshift duplication           V154fs           rs772486760    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 2 February 2015)
  182036         215646150              C      T      nonsense                         R150 \*          rs730881411    0.00001                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 29 July 2016)
  185139         215657051              C      T      nonsense                         R112 \*          rs758972589    0.00001                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 27 May 2016)
  185079         215657087              C      T      nonsense                         Q100 \*          rs786201912    .                            Familial cancer of breast\|Hereditary cancer-predisposing syndrome                       Pathogenic (Last reviewed: 13 December 2016)
  230447         215657108              C      T      nonsense                         Q93 \*           rs876658571    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 23 February 2015)
  231019         215657170              G      A      splice acceptor                  .                rs876658905    .                            Hereditary cancer-predisposing syndrome                                                  Likely pathogenic (Last reviewed: 26 March 2015)
  371931         215661823--215661824   AG     \-     frameshift deletion              E59fs            rs1057517589   .                            Familial cancer of breast                                                                Pathogenic/Likely pathogenic (Last reviewed: 16 November 2016)
  246176         215661842              G      T      splice acceptor                  .                rs879254139    .                            not provided                                                                             Likely pathogenic (Last reviewed: 3 December 2015)
  246476         215674192              G      A      nonsense                         W34 \*           rs879254280    .                            not provided                                                                             Likely pathogenic (Last reviewed: 8 March 2016)
  231232         215674224--215674225                 frameshift indel                 A25fs            rs876659040    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 25 March 2015)
  233594         215674239              G      T      nonsense                         E19 \*           rs752514155    0.00002                      Familial cancer of breast\|not provided\|Hereditary cancer-predisposing syndrome         Pathogenic (Last reviewed: 28 August 2016)
  232926         215674271--215674290                 frameshift deletion              P2fs             rs876660077    .                            Hereditary cancer-predisposing syndrome                                                  Pathogenic (Last reviewed: 10 July 2015)
  127739         215674291              G      A      missense                         M1I              rs587780031    .                            not provided                                                                             Pathogenic (Last reviewed: 5 November 2013)
  154206         190300875--242783384   .      .      copy number gain (2q32.2-37.3)   .                nssv3395386    .                            Hypospadias                                                                              Pathogenic (Last reviewed: 18 March 2014)
  152738         193803552--216569775   .      .      copy number loss (2q32.3-35)     .                nssv1608180    .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 14 January 2013)
  150620         181378520--225167565   .      .      copy number gain (2q31.3-36.1)   .                nssv1604018    .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 25 July 2011)
  146683         211444400--243059659   .      .      copy number gain (2q34-37.3)     .                nssv706486     .                            Coarctation of aorta                                                                     Pathogenic (Last reviewed: 25 February 2011)
  59164          213479146--227985946   .      .      copy number gain (2q34-36)       .                nssv578841     .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 12 August 2011)
  59160          193987039--242014395   .      .      copy number gain (2q32.3-37.3)   .                nssv578835     .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 12 August 2011)
  59159          191175462--242834921   .      .      copy number gain (2q32.2-37.3)   .                nssv578834     .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 12 August 2011)
  59158          189682921--243007359   .      .      copy number gain (2q32.2-37.3)   .                nssv578833     .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 12 August 2011)
  57419          195763507--237382556   .      .      copy number gain (2q32.3-37.3)   .                nssv578837     .                            Developmental delay AND/OR other significant developmental or morphological phenotypes   Pathogenic (Last reviewed: 12 August 2011)

\*: truncated protein.
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Somatic mutations of *BARD1* deposited in COSMIC database with pathogenicity statistical significance.

  Position    Sequence Ontology   Protein Sequence Change   CHASM *p*-Value   VEST *p*-Value   ID dbSNP      Frequency in ExAC Database   COSMIC Variant Count in Tissues (*n*)
  ----------- ------------------- ------------------------- ----------------- ---------------- ------------- ---------------------------- ---------------------------------------------------------
  214769310   SG                  R123 \*                                     0.1290           rs369986649   0.00                         large_intestine (1); lung (1); endometrium (1); skin(2)
  214781072   MS                  E268K                     0.2724            0.4382                         0.00                         cervix(1); liver(2)
  214728840   MS                  A724T                     0.0462            0.0145                         0.00                         large_intestine(2)
  214730417   MS                  E665D                     0.3204            0.5076                         0.00                         liver(2)
  214728936   MS                  I692F                     0.4718            0.2635                         0.00                         liver(2)
  214781454   MS                  K140N                     0.5620            0.1730           rs758749603   0.000008                     large_intestine(1); endometrium(1)
  214781285   SG                  K197 \*                                     0.2026                         0.00                         liver(2)
  214781251   FD                  K208RKL \*                                  0.0588                         0.000017                     large_intestine(1)
  214780799   SY                  L359L                                                                      0.00                         esophagus(2)
  214730452   MS                  P654S                     0.0970            0.6800                         0.00                         skin(2)
  214792396   MS                  P89A                      0.2542            0.0534                         0.00                         pancreas(2)
  214728907   MS                  Q701H                     0.1730            0.1709                         0.00                         esophagus(1)
  214781390   MS                  S162A                     0.5712            0.2689                         0.00                         hematopoietic_and_lymphoid_tissue(2)
  214780783   MS                  S364L                     0.4934            0.7981           rs200168806   0.00                         esophagus(2)
  214780784   MS                  S364T                     0.7164            0.3940           rs201292946   0.00                         esophagus(2)
  214780955   MS                  Y307N                     0.6760            0.5594                         0.00                         esophagus(1)
  214769314   SS                                                              0.0374                         0.00                         
  214781510   SS                                                              0.1037                         0.00                         
  214728990   SG                  G674 \*                                     0.0577                         0.00                         
  214745084   SG                  W629 \*                                     0.0191           rs747446711   0.000008                     lung(1)
  214780882   MS                  P331R                     0.6070            0.2104                         0.00                         autonomic_ganglia(1)
  214780655   MS                  V407M                     0.2596            0.8458                         0.00                         biliary_tract(1)
  214781361   \^ FD               see footnote                                0.2006                         0.000016                     biliary_tract(1)
  214781136   SY                  P246P                                                        rs587780859   0.000096                     bone(1)
  214781165   MS                  Q237E                     0.4816            0.8826           rs587780035   0.000096                     bone(1)
  214745777   SY                  L585L                                                                      0.00                         breast(1)
  214745791   MS                  Q581K                     0.3898            0.0927                         0.00                         breast(1)
  214792394   SY                  P89P                                                         rs756165637   0.000008                     breast(1)
  214781066   MS                  E270K                     0.3180            0.3405                         0.00                         cervix(1)
  214781210   MS                  A222S                     0.8046            0.7358                         0.00                         cervix(1)
  214781384   SG                  Q164 \*                                     0.1407                         0.00                         endometrium(1)
  214781306   MS                  D190Y                     0.6800            0.5193           rs369561166   0.000008                     endometrium(1)
  214781158   MS                  L239R                     0.4934            0.5867                         0.00                         endometrium(1)
  214780657   MS                  R406Q                     0.6028            0.7262           rs587780014   0.0000412                    endometrium(1)
  214730490   MS                  R641Q                     0.2660            0.6668           rs752870879   0.0000082                    endometrium(1)
  214781449   SG                  S142 \*                                     0.1272                         0.00                         endometrium(1)
  214745097   MS                  L625I                     0.5980            0.2316                         0.00                         endometrium(1)
  214780981   MS                  V298A                     0.4174            0.9235                         0.00                         endometrium(1)
  214728928   SY                  L694L                                                        rs139620052   0.000157                     endometrium(1)
  214745741   SY                  Y597Y                                                                      0.00                         endometrium(1)
  214767501   MS                  G517R                     0.2520            0.0149                         0.00                         hematopoietic_and_lymphoid_tissue(1)
  214767558   MS                  L498I                     0.1770            0.0629                         0.00                         
  214730463   MS                  K650T                     0.3204            0.2411                         0.00                         kidney(1)
  214767483   MS                  V523I                     0.2358            0.4735                         0.00                         kidney(1)
  214767560   MS                  P497L                     0.0730            0.0046                         0.00                         kidney(1)
  214781275   MS                  A200V                     0.3100            0.7394                         0.00                         kidney(1)
  214792349   MS                  M104I                     0.1630            0.0450           rs752133770   0.000008                     kidney(1)
  214728757   SY                  R751R                                                        rs750001065   0.00                         large_intestine(1)
  214728786   MS                  L742V                     0.4234            0.7816                         0.00                         large_intestine(1)
  214728839   MS                  A724V                     0.0356            0.0153           rs587782662   0.000041                     large_intestine(1)
  214728971   SG                  W680 \*                                     0.0967                         0.00                         large_intestine(1)
  214745779   MS                  L585F                     0.2630            0.0431                         0.00                         large_intestine(1)
  214752448   MS                  V559A                     0.0894            0.2909                         0.00                         large_intestine(1)
  214767651   MS                  E467K                     0.1858            0.0168                         0.00                         large_intestine(1)
  214780632   MS                  M414I                     0.7050            0.5045                         0.00                         large_intestine(1)
  214780885   MS                  S330I                     0.6160            0.6216                         0.00                         large_intestine(1)
  214780904   MS                  H324N                     0.6444            0.6244                         0.00                         large_intestine(1)
  214780960   MS                  K305T                     0.7818            0.5088                         0.00                         large_intestine(1)
  214780974   SY                  P300P                                                                      0.00                         large_intestine(1)
  214781327   MS                  V183L                     0.5944            0.3666                         0.00                         large_intestine(1)
  214781495   MS                  K127E                     0.7706            0.7394                         0.00                         
  214792327   SG                  R112 \*                                     0.0323           rs758972589   0.000008                     large_intestine(1)
  214752523   MS                  T534K                     0.3864            0.0564                         0.00                         
  214752535   MS                  P530L                     0.0214            0.0078                         0.00                         liver(1)
  214781157   SY                  L239L                                                        rs760951875   0.000009                     
  214781422   MS                  S151N                     0.3204            0.1398                         0.00                         liver(1)
  214792355   MS                  D102E                     0.5138            0.1463                         0.00                         
  214809564   SY                  P2P                                                                        0.00                         liver(1)
  214728989   MS                  G674V                     0.1270            0.0055                         0.00                         lung(1)
  214730432   MS                  S660R                     0.2322            0.0874                         0.00                         lung(1)
  214745727   MS                  S602I                     0.6860            0.1905                         0.00                         lung(1)
  214745805   MS                  G576V                     0.4174            0.1383                         0.00                         lung(1)
  214752450   SY                  S558S                                                                      0.00                         lung(1)
  214767507   MS                  S515A                     0.5474            0.5937                         0.00                         lung(1)
  214767582   MS                  T490P                     0.4354            0.5565                         0.00                         lung(1)
  214780637   MS                  A413T                     0.3100            0.8492                         0.00                         lung(1)
  214780642   MS                  P411H                     0.3420            0.0515                         0.00                         lung(1)
  214780818   SY                  V352V                                                        rs768469265   0.000008                     lung(1)
  214780842   MS                  S344R                     0.6530            0.5045                         0.00                         lung(1)
  214780856   MS                  I340F                     0.8810            0.8826                         0.00                         
  214781201   MS                  E225K                     0.2884            0.6445                         0.00                         
  214781353   MS                  S174I                     0.7774            0.7572                         0.00                         lung(1)
  214781387   MS                  V163M                     0.2284            0.3354                         0.00                         lung(1)
  214797074   MS                  H68Y                      0.0190            0.0139                         0.00                         
  214809509   MS                  R21C                      0.2122            0.7193                         0.00                         lung(1)
  214769252   MS                  H459Y                     0.2160            0.2473                         0.00                         NS(1)
  214769253   SY                  D458D                                                                      0.00                         NS(1)
  214769270   MS                  D453N                     0.2630            0.1696                         0.00                         NS(1)
  214809491   MS                  E27K                      0.1308            0.5288                         0.00                         NS(1)
  214728731   MS                  S760L                     0.2122            0.0823           rs730881425   0.000025                     esophagus(1)
  214728819   MS                  R731C                     0.2852            0.3666           rs76744638    0.000041                     esophagus(1)
  214745127   MS                  Q615E                     0.4234            0.1915           rs751710099   0.000008                     esophagus(1)
  214767505   SY                  S515S                                                                      0.00                         esophagus(1)
  214767573   MS                  Q493E                     0.5370            0.5719                         0.00                         esophagus(1)
  214780709   MS                  S389R                     0.5944            0.4714                         0.00                         esophagus(1)
  214781120   MS                  P252S                     0.3204            0.8220           rs758368819   0.000009                     esophagus(1)
  214781351   MS                  A175P                     0.8810            0.4547                         0.00                         esophagus(1)
  214745744   SY                  K596K                                                        rs777084777   0.000066                     pancreas(1)
  214752510   SY                  S538S                                                        rs781448650   0.000016                     pancreas(1)
  214767635   MS                  G472E                     0.1042            0.0035                         0.00                         pancreas(1)
  214792385   MS                  I92M                      0.4354            0.2288                         0.00                         pancreas(1)
  214780909   MS                  R322H                     0.6340            0.7262           rs774251286   0.000017                     pituitary(1)
  214730417   SY                  E665E                                                                      0.00                         prostate(1)
  214752536   MS                  P530S                     0.0144            0.0102           rs760144724   0.000008                     prostate(1)
  214769261   MS                  V456I                     0.1904            0.4630                         0.00                         prostate(1)
  214781033   MS                  P281S                     0.1358            0.6871           rs200059956   0.000017                     prostate(1)
  214781127   SY                  I249I                                                        rs746551077   0.000009                     prostate(1)
  214781355   SY                  A173A                                                                      0.00                         prostate(1)
  214728723   MS                  F763V                     0.6444            0.3044           rs761586960   0.000008                     skin(1)
  214730442   MS                  P657L                     0.0304            0.0144                         0.00                         skin(1)
  214730443   MS                  P657S                     0.1270            0.1673                         0.00                         
  214745129   MS                  V614A                     0.1114            0.5492                         0.00                         skin(1)
  214745834   SY                  R566R                                                                      0.00                         skin(1)
  214767584   MS                  T489I                     0.1730            0.2288                         0.00                         skin(1)
  214767639   MS                  H471Y                     0.2284            0.1872           rs867587389   0.00                         skin(1)
  214769288   MS                  L447F                     0.1204            0.0426                         0.00                         skin(1)
  214780570   MS                  A435V                     0.3420            0.0168                         0.00                         skin(1)
  214780609   MS                  V422G                     0.8136            0.8197           rs76824305    0.000232                     skin(1)
  214780643   MS                  P411S                     0.0962            0.1509                         0.00                         skin(1)
  214780882   MS                  P331L                     0.3898            0.2518                         0.00                         skin(1)
  214781320   MS                  P185L                     0.4934            0.8492                         0.00                         skin(1)
  214781323   MS                  S184F                     0.1858            0.2233           rs184660818   0.00                         skin(1)
  214792395   MS                  P89Q                      0.1056            0.0249                         0.00                         skin(1)
  214792396   MS                  P89S                      0.0212            0.0417                         0.00                         skin(1)
  214809508   MS                  R21L                      0.2038            0.6894                         0.00                         skin(1)
  214728752   MS                  G753D                     0.0762            0.0168           rs867281641   0.00                         stomach(1)
  214728780   MS                  N744D                     0.5416            0.4141                         0.00                         stomach(1)
  214728831   MS                  D727N                     0.3044            0.5867           rs730881424   0.000025                     stomach(1)
  214728891   MS                  P707S                     0.0436            0.0289                         0.00                         stomach(1)
  214728985   SY                  C675C                                                                      0.00                         stomach(1)
  214730411   SY                  L667L                                                                      0.00                         stomach(1)
  214767511   SY                  L513L                                                                      0.00                         stomach(1)
  214767611   MS                  L480S                     0.1242            0.0086           rs149839922   0.000008                     stomach(1)
  214769254   MS                  D458V                     0.0432            0.0034                         0.00                         stomach(1)
  214780751   MS                  T375A                     0.5088            0.8954                         0.00                         stomach(1)
  214781250   FI                  K208KENFS \*                                0.0618           rs587780033   0.000017                     stomach(1)
  214781418   SY                  K152K                                                                      0.00                         stomach(1)
  214792416   MS                  G82V                      0.4234            0.2775                         0.00                         stomach(1)
  214745083   MS                  W629C                     0.1678            0.0025                         0.00                         
  214781258   MS                  Q206K                     0.4174            0.6353                         0.00                         
  214728689   MS                  P774L                     0.3692            0.1073                         0.00                         upper_aerodigestive_tract(1)
  214745730   MS                  D601G                     0.6122            0.1612           rs767765131   0.000016                     
  214769271   MS                  S452R                     0.5370            0.1476                         0.00                         upper_aerodigestive_tract(1)
  214781182   MS                  S231C                     0.5654            0.5912                         0.00                         upper_aerodigestive_tract(1)
  214809454   MS                  A39G                      0.5572            0.4215                         0.00                         
  214745154   MS                  H606D                     0.1552            0.0017                         0.00                         urinary_tract(1)
  214781269   MS                  S202C                     0.3982            0.4655                         0.00                         urinary_tract(1)

SG: Stop Gain; MS: Missense; FD: Frameshift Deletion; SY: Synonymous; SS: Splicing Site; FI: Frameshift Insertion; \*: truncated proteins; \^: protein deletion K171KMQVLSKTHMNLFPQVLLQMFLRGLKRLLQDLEKSKKRKL; ID dbSNP: Nomenclature of the single nucleotide polymorphism; Exac database (<http://exac.broadinstitute.org/>): Exome Aggregation Consortium is a database that reports the frequency of variants from a wide variety of large-scale sequencing projects, CHASM: Cancer-specific High-throughput Annotation of Somatic Mutations; VEST: Variant Effect Scoring Tool.
